PET/SPECT imaging agents for neurodegenerative diseases.

Single photon emission computed tomography (SPECT) or positron emission computed tomography (PET) imaging agents for neurodegenerative diseases have a significant impact on clinical diagnosis and patient care. The examples of Parkinson's Disease (PD) and Alzheimer's Disease (AD) imaging agents described in this paper provide a general view on how imaging agents, i.e. radioactive drugs, are selected, chemically prepared and applied in humans. Imaging the living human brain can provide unique information on the pathology and progression of neurodegenerative diseases, such as AD and PD. The imaging method will also facilitate preclinical and clinical trials of new drugs offering specific information related to drug binding sites in the brain. In the future, chemists will continue to play important roles in identifying specific targets, synthesizing target-specific probes for screening and ultimately testing them by in vitro and in vivo assays.

[1]  E. Rabiner,et al.  Translational PET imaging research , 2014, Neurobiology of Disease.

[2]  Lin Zhu,et al.  Expanding the Scope of Fluorine Tags for PET Imaging , 2013, Science.

[3]  Keith A. Johnson,et al.  Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging , 2013, Alzheimer's & Dementia.

[4]  S. Kapur,et al.  Molecular imaging as a guide for the treatment of central nervous system disorders , 2013, Dialogues in clinical neuroscience.

[5]  F. Tarazi,et al.  Bapineuzumab and solanezumab for Alzheimer's disease: is the ‘amyloid cascade hypothesis' still alive? , 2013, Expert opinion on biological therapy.

[6]  Colin L. Masters,et al.  Head-to-Head Comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-Amyloid Imaging in Aging and Dementia , 2013, The Journal of Nuclear Medicine.

[7]  L. Chen,et al.  Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligand. , 2013, Journal of medicinal chemistry.

[8]  W. Klunk,et al.  Development and Screening of Contrast Agents for In Vivo Imaging of Parkinson’s Disease , 2013, Molecular Imaging and Biology.

[9]  M. Goodman,et al.  Fluorine-18 radiolabeled heterocycles as PET tracers for imaging β-amyloid plaques in Alzheimer's disease. , 2013, Current topics in medicinal chemistry.

[10]  N. Petry,et al.  The Future of USP Monographs for PET Drugs , 2013, The Journal of Nuclear Medicine.

[11]  John Seibyl,et al.  Neuroimaging over the course of Parkinson's disease: from early detection of the at-risk patient to improving pharmacotherapy of later-stage disease. , 2012, Seminars in nuclear medicine.

[12]  W. Klunk,et al.  Development of positron emission tomography β-amyloid plaque imaging agents. , 2012, Seminars in nuclear medicine.

[13]  Ewen Callaway,et al.  Alzheimer’s drugs take a new tack , 2012, Nature.

[14]  C. Masters,et al.  The challenges of tau imaging , 2012 .

[15]  Hank F Kung,et al.  The β-Amyloid Hypothesis in Alzheimer's Disease: Seeing Is Believing. , 2012, ACS medicinal chemistry letters.

[16]  David J. Brooks,et al.  Imaging biomarkers in Parkinson's disease , 2011, Progress in Neurobiology.

[17]  Diana Paez,et al.  Trends in Nuclear Medicine in Developing Countries , 2011, The Journal of Nuclear Medicine.

[18]  C. Rowe,et al.  In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease. , 2011, Archives of neurology.

[19]  Henry VanBrocklin,et al.  FDA cGMP requirements for PET drugs. , 2011, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  R. Coleman,et al.  Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.

[21]  E. Salmon,et al.  18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.

[22]  D. Skovronsky,et al.  18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective. , 2010, Journal of medicinal chemistry.

[23]  C. Rowe,et al.  In Vivo Measurement of Vesicular Monoamine Transporter Type 2 Density in Parkinson Disease with 18F-AV-133 , 2010, Journal of Nuclear Medicine.

[24]  B. Långström,et al.  The use of PET in Alzheimer disease , 2010, Nature Reviews Neurology.

[25]  J. Seibyl.  Single-photon emission computed tomography and positron emission tomography evaluations of patients with central motor disorders. , 2008, Seminars in nuclear medicine.

[26]  Sanjiv Sam Gambhir,et al.  Molecualr imaging of cancer: from molecules to humans. Introduction. , 2008, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  Pius August Schubiger,et al.  Molecular imaging with PET. , 2008, Chemical reviews.

[28]  Habib Zaidi,et al.  PET versus SPECT: strengths, limitations and challenges , 2008, Nuclear medicine communications.

[29]  H. Kung,et al.  Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters. , 2007, Nuclear medicine and biology.

[30]  N. Bohnen,et al.  Positron Emission Tomography of Monoaminergic Vesicular Binding in Aging and Parkinson Disease , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[31]  R. Weissleder.  Molecular Imaging in Cancer , 2006, Science.

[32]  P. Moberg,et al.  [99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease , 2005, Neurology.

[33]  S. Cherry,et al.  Physics in Nuclear Medicine , 2004 .

[34]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[35]  Klaus Tatsch,et al.  Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson’s disease? , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[36]  M. Kung,et al.  Novel stilbenes as probes for amyloid plaques. , 2001, Journal of the American Chemical Society.

[37]  S. Jurisson,et al.  Potential technetium small molecule radiopharmaceuticals. , 1999, Chemical reviews.

[38]  S. Gilman,et al.  Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging , 1996, Annals of neurology.

[39]  K. Frey,et al.  Striatal concentrations of vesicular monoamine transporters are identical in MPTP-sensitive (C57BL/6) and -insensitive (CD-1) mouse strains. , 1996, European journal of pharmacology.

[40]  Y. Agid,et al.  [3H]Dihydrotetrabenazine, a New In Vitro Monoaminergic Probe for Human Brain , 1988, Journal of neurochemistry.

[41]  K. Hamacher,et al.  Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  A. Wolf,et al.  A shielded synthesis system for production of 2-deoxy-2-[18F]fluoro-D-glucose. , 1981, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[43]  A. Pletscher,et al.  A benzo[a]quinolizine derivative with a neuroleptic-like action on cerebral monoamine turnover. , 1977, The Journal of pharmacology and experimental therapeutics.

[44]  J. Wiener,et al.  The impact of DaTscan on the diagnosis and management of movement disorders: A retrospective study. , 2013, American journal of neurodegenerative disease.

[45]  W. Marsden.  I and J , 2012 .

[46]  J. Zubieta,et al.  New directions in the coordination chemistry of 99mTc: a reflection on technetium core structures and a strategy for new chelate design. , 2005, Nuclear medicine and biology.